Related Experiment Video
Updated: Aug 29, 2026
Hand-Rearing Method for Infant Marmosets
Published on: June 9, 2023
Modafinil prevents the MPTP-induced increase in GABAA receptor binding in the internal globus pallidus of
B-Y Zeng1, L A Smith, R K B Pearce
1Neurodegenerative Disease Research Centre, Guy's, King's and St Thomas' School of Biomedical Sciences, King's College, London SE1 1UL, UK.
Abstract:
The psychostimulant drug modafinil induces a reversal of motor deficits in MPTP treated primates and prevents MPTP toxicity to substantia nigra but its mechanism of action is not clear. In common marmosets acutely treated with MPTP in the presence or absence of modafinil, we have studied changes in GABA(A) receptor binding in the basal ganglia. MPTP treatment had no effect on [(3)H]-flunitrazepam (FNZ) binding density in the striatum or external globus pallidus (GPe) but increased [(3)H]-FNZ binding density in the internal globus pallidus (GPi). Administration of modafinil (10-100 mg/kg) with MPTP did not alter [(3)H]-FNZ binding density in the striatum or GPe. Low doses of modafinil (10 and 30 mg/kg) had no effect on the increased [(3)H]-FNZ binding density in the GPi but high dose modafinil (100 mg/kg) significantly decreased [(3)H]-FNZ binding density in GPi. These findings suggest that modafinil can selectively alter GABA binding density in the GPi either by preventing MPTP-induced toxicity or through an action on striatal output pathway related to its antiparkinsonian activity and its ability to inhibit MPTP toxicity.
Insights
Modafinil may reverse motor deficits in Parkinsonism by altering GABA(A) receptor binding in the brain. High doses of modafinil selectively decreased this binding in the internal globus pallidus, suggesting a novel therapeutic mechanism.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Modafinil (a psychostimulant) reverses motor deficits in MPTP-treated primates and prevents MPTP toxicity.
- The precise mechanism of modafinil's action, particularly concerning its effects on the basal ganglia and GABAergic systems, remains unclear.
Purpose of the Study:
- To investigate the effects of modafinil on GABA(A) receptor binding density in the basal ganglia of MPTP-treated common marmosets.
- To elucidate the mechanism underlying modafinil's neuroprotective and motor-improving effects in Parkinsonism models.
Main Methods:
- Common marmosets were treated with MPTP (a Parkinsonism-inducing neurotoxin) in the presence or absence of varying doses of modafinil.
- GABA(A) receptor binding was assessed using [(3)H]-flunitrazepam (FNZ) binding density measurements in the striatum, external globus pallidus (GPe), and internal globus pallidus (GPi).
Main Results:
- MPTP treatment increased [(3)H]-FNZ binding density in the internal globus pallidus (GPi) but not in the striatum or external globus pallidus (GPe).
- Modafinil (10-100 mg/kg) did not alter binding in the striatum or GPe.
- Low doses of modafinil (10, 30 mg/kg) did not affect the MPTP-induced increase in GPi binding, but a high dose (100 mg/kg) significantly decreased it.
Conclusions:
- Modafinil selectively alters GABA(A) receptor binding density in the internal globus pallidus (GPi).
- This effect may be related to modafinil's ability to prevent MPTP toxicity or modulate striatal output pathways, contributing to its antiparkinsonian activity.
